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Putting T cells to sleep: a new paradigm for immune evasion by 
persistent viruses
The elimination of a viral pathogen from the host is critically dependent upon a robust immune response, 
initiated by the humoral (employing antibodies) and cellular (employing cytotoxic T cells) arms of the 
immune system. Viruses that cause persistent infections in vertebrates employ various strategies to evade 
these host immune responses, in addition to effects on cell signalling and cell death pathways. In the last 
few months, a series of papers have described a new pathway of immune evasion by persistent viruses. 
The central theme of this strategy is to silence antigen (virus)-specifi c CD4+ (helper) cells that promote 
development of a robust immune response and CD8+ (cytotoxic) T cells that seek out and destroy virus-
infected cells. The central player in this strategy is a protein called PD-1 and its ligands PD-L1 and PD-L2. 
Induction of PD-1 expression on T cells inhibits T cell activation and effector functions thereby preventing 
elimination of the virus. This would allow the virus to evade immune surveillance and persist in the host. 
The programmed death-1 (PD-1) receptor was isolated in 1992 by subtractive hybridization as a 
molecule whose expression was enhanced following apoptotic stimulation of T cells (Ishida et al 1992). 
It belongs to the CD28 family of immunoreceptors and is expressed on activated B, T and myeloid cells. 
Till date, two PD-1 ligands have been identifi ed; these are PD-L1 (also called B7H-1) and PD-L2 (also 
called B7-DC) (Khoury and Sayegh 2004). PD-L1 is expressed on T cells, B cells, macrophages and 
dendritic cells (DCs) and is upregulated following activation of these cells. In contrast, PD-L2 expression 
is only inducible on DCs and macrophages. Though the exact function of these ligands still needs to be 
elucidated, available data suggests that ligation of PD-1 triggers an inhibitory signalling pathway in the 
PD-1 expressing cells. Similar to other CD28 family members, PD-1 transduces an inhibitory signal only 
when engaged in combination with T cell receptor (TCR) ligation, but not when cross-linked on its own. 
However, the precise signalling pathways through which PD-1 transduces signals are not fully understood. 
The inhibitory activity of PD-1 depends upon association of the tyrosine phosphatase SHP-2 with its 
immunoreceptor tyrosine based switch motif (ISTM) rather than its immunoreceptor tyrosine based 
inhibitory motif (ITIM), more typically associated with inhibitory receptors (Latchman et al 2001). These 
features are schematically illustrated in fi gure 1.
The role of PD-1 in immunoregulation has been explored widely in autoimmune diseases and tumours 
(Dong and Chen 2003; Iwai et al 2002; Okazaki and Honjo 2006). PD-1 knockout mice exhibit features 
of autoimmunity, which led to the hypothesis that PD-1 is an important player in regulating autoreactive 
responses (Nishimura et al 1999). The expression of PD-L1 or B7-H1, on tumour cells of a variety of 
histologies has suggested a potential mechanism for tumour escape from immune destruction (Dong and 
Chen 2003; Dong et al 2002). Recent data has now demonstrated that the PD-1 inhibitory pathway, in 
addition to regulating T cell responses to self-antigens and tumours, also regulates CD4+ and CD8+ T cell 
responses to persistent viruses.
To examine the mechanisms of T cell dysfunction during persistent infection, Barber et al (2006) used 
the mouse model of infection with lymphocytic choreomeningitis virus (LCMV). An advantage of this 
model is the availability of LCMV strains that can cause either acute or chronic infection in adult mice. 
The Armstrong strain of LCMV is cleared within a week and a population of antigen-specifi c memory T 
cells is established, whereas clone 13 establishes a persistent infection that render the T cells functionally 
impaired or ‘exhausted’. A gene expression array analysis showed that exhausted virus-specifi c CD8+ 
T cells from clone 13 infection had signifi cantly higher PD-1 expression, compared to the functional 
antigen-specifi c T cells that develop following infection with the Armstrong strain. The CD8+ T cells from 
chronically infected mice maintained higher levels of PD-1 expression. Moreover expression of one of the 
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ligands for this receptor, PD-L1, was also upregulated on mouse splenocytes. Remarkably, compared to 
untreated animals, chronically infected mice that were treated with a PD-L1-specifi c antibody displayed 
a marked expansion of functional virus-specifi c CD8+ T-cells characterized by an increased ability to 
produce interferon-γ and tumour necrosis factor, thereby reversing the ‘exhausted’ phenotype. In addition, 
PD-L1 blockade markedly reduced the viral load and resolved infection with the persistent clone 13 strain 
(Barber et al 2006). While it was not clear whether the aberrant expression of PD-1 and PD-L1 was a 
cause or effect of chronic infection, an inhibition of this receptor-ligand interaction led to recovery of 
functional T cell responses and the clearance of an otherwise chronic virus. 
Do these fi ndings with a mouse virus have a parallel in persistent viral infections of humans? This was 
indeed the case for persons infected with the human immunodefi ciency virus (HIV).
Day et al (2006) studied a cohort of HIV-infected individuals from KwaZulu Natal province in 
South Africa, where seroprevalence rates for HIV are in excess of 30% in certain age groups. Antigen 
specifi c CD8+ T cells in 71 people who were not receiving any antiretroviral therapy exhibited signifi cant 
upregulation of PD-1 expression. This correlated positively with parameters of disease progression such as 
plasma viral load (as measured by the amount of HIV RNA copies in blood) and loss of CD4+ T cells. PD-
1 expression was also analysed on cytomegalovirus (CMV)-specifi c, Epstein-Barr virus (EBV)-specifi c 
and vaccinia virus (VV)-specifi c CD8+ T cells from individuals who were not infected with HIV. It was 
found to be intermediate on CMV-specifi c T cells, high for an EBV lytic epitope and low for VV-specifi c 
T cells indicating a relationship between ongoing antigen exposure and PD-1 expression (Day et al 2006). 
In this study, upregulation of PD-1 was uniquely observed on HIV-specifi c CD8+ T cells since another 
inhibitory receptor, CTLA-4, was not found to be upregulated on HIV-specifi c T cells. This implies that 
chronic infection specifi cally upregulates the PD-1 inhibitory receptor. The expression of PD-1 on CD4+ 
T cells also showed a positive correlation with viral loads and loss of CD4+ cells. Importantly, blockade 
of the PD-1/PD-L1 pathway signifi cantly restored both the number and functional competence of HIV 
specifi c CD8+ T cells. 
Figure 1. Schematic representation of activating (CD28) and inhibitory (PD-1 and CTLA-4) receptors on T cells 
and their respective ligands on APCs. The arrows indicate binding of either B7.1 or B7.2 to CD28 or CTLA-4. The 
plus and minus signs indicate transduction of activating and inhibitory signals respectively, after receptor ligand 
interaction. The red dot indicates immunoreceptor tyrosine based inhibitory motif (ITIM) in the cytoplasmic tail of 
CTLA-4 and PD-1 receptor, the green dot represents immunoreceptor tyrosine based switch motif (ISTM) found only 
in the cytoplasmic tail of PD-1 receptor and the blue dot indicates the domain in CD28 receptor which transduces 
activating signals.
Clipboard 499
J. Biosci. 31(5), December 2006
Similar results were obtained in a related study carried out on a HIV cohort in Montreal, Canada. 
Trautman et al (2006) demonstrated that PD-1 was upregulated on HIV-specifi c CD8+ T cells and not on 
CMV-specifi c T cells. The expression levels of PD-1 correlated with viral loads and the reduced ability of 
HIV-specifi c CD8+ T cells to proliferate or produce cytokines. Blocking the interaction of PD-1 with PD-
L1 enhanced the capacity of HIV-specifi c CD8+ T cells to proliferate and produce cytokines (Trautmann 
et al 2006). 
Apart from increased expression of PD-1 on T cells, expression of one of its ligands, PD-L1, was 
shown to be upregulated on monocytes from HIV patients (Trabattoni et al 2003). The PD-L1 expressing 
CD14+ cells also produced more IL-10 in these patients and upregulation of PD-L1 correlated with plasma 
viral loads (Trabattoni et al 2003).
Petrovas et al (2006) have revealed another interesting aspect of PD-1 upregulation on HIV-specifi c 
T cells. According to this study, PD-1 expression is crucial for regulating the survival of virus-specifi c 
CD8+ T cells during HIV infection. Expression of PD-1 was found to be higher on memory CD8+ T 
cells according to antigen specifi city. For instance, memory CD8+ T cells specifi c for a poorly controlled 
persistent infection like HIV showed higher expression of PD-1 compared to memory T cells-specifi c for 
a well-controlled persistent virus (cytomegalovirus) or a virus causing acute infection (vaccinia virus). 
Interestingly, PD-1 expression was the sole determinant of sensitivity of virus-specifi c T cells to apoptosis 
and was not directly associated with the inability of CD8+ T cells to produce cytokines. In other words, 
enhanced expression of PD-1 on CD8+ T cells in HIV infection is proposed to predispose these cells to 
apoptosis, resulting in decreased frequency of antiviral T cells. Manipulation of PD-1 expression could 
infl uence the ability of these cells to survive and expand which in turn led to increased numbers of cells 
becoming functional in producing cytokines (Petrovas et al 2006). A model for PD-1 mediated T cell 
exhaustion is presented in fi gure 2.
Similar CD8+ T cell exhaustion has also been reported for infection with another successful persistent 
human viral pathogen, the hepatitis C virus (HCV). High levels of PD-1 expression were observed 
on HCV-specifi c CD8+ T cells in persons with persistent HCV infection (Urbani et al 2006). The 
expression of PD-L1 on hepatocytes has been shown to be strongly enhanced by activated T cells and 
viral infection, and markedly augmented by type I or type II interferons. Moreover, PD-L1 expression on 
hepatocytes induced apoptosis in T cells (Muhlbauer et al 2006). A role for epithelial PD-L1 and PD-L2 in
Figure 2. Schematic representation of PD-1/PD-L1 interaction in persistent infection. Antigen specifi c memory 
T cells produced after an acute infection are able to clear the virus because the cytotoxic ability of CD8 T cells is 
functional. Infection by a persistent virus induces expression of PD-1 and PD-L1 on T cells and APCs, respectively, 
which either reduces the frequency of antiviral T cells by inducing apoptosis or loss of survival signals, or lowers their 
cytotoxic function by inhibiting IFN-γ production.
Clipboard500
J. Biosci. 31(5), December 2006
virus-initiated immune responsiveness in the airways has also been suggested in the context of a viral 
infection (Tsuda et al 2005) . 
Recently, an immunoregulatory role has been proposed for the PD-1/PD-L1 interaction in liver. Naïve 
self-reactive T cells in the liver may get activated due to their cross-reactivity to some viral antigens. 
The regulation by PD-1 prevents undesirable or excessive activation of effector T cells in peripheral
organs such as liver (Iwai et al 2003). Although these safeguards are critical for the avoidance of 
autoimmunity, they may restrict the host’s ability to counteract infectious agents. Some pathogens can 
therefore escape from surveillance of the host immune system and cause chronic infection. The fact that 
the absence of a PD-1 inhibitory signal can augment antiviral immunity has signifi cant implications for 
not only an understanding of the pathogenic mechanism but also for the treatment of persistent infection 
of the liver.
It will be worth investigating why of the roughly 30 receptors known to exert inhibitory effects on 
lymphocytes and other cells of the immune system, PD-1 is a central regulator of T cell exhaustion during 
persistent infection. Characterization of the structure, function and expression of the PD-1 receptor will be 
important for further understanding its role in regulating immune responses and designing more directed 
therapeutic strategies. 
These studies offer possible new candidates that may be used for therapeutic intervention in HIV, 
HCV and other persistent infections. Although the number of inhibitory candidates that can be targeted 
in persistent viral infection is relatively small, these results should also be viewed with caution when 
considering their therapeutic importance given that the PD-1/PD-L1 pathway is important in preventing 
activation of autoreactive T cells. 
Nevertheless, the discovery of PD-1/PD-L1 effects in persistent viral infections offers new insight 
into immune evasion by viruses. Further investigations of this signalling pathway will be of immense 
importance for understanding the mechanistic complexities involved in the interplay between viruses and 
their hosts.
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